2017

Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation
Döring M, Cabanillas Stanchi K, Queudeville M, Feucht J, Blaeschke F, Schlegel P, Feuchtinger T, Lang P, Müller I, Handgretinger R, Heinz W
J CANCER RES CLIN. 2017 [Epub ahead of print].

Mutations in EXTL3 Cause Neuro-immuno-skeletal Dysplasia Syndrome
Oud M, Tuijnenburg P, Hempel M, van Vlies N, Ren Z, Ferdinandusse S, Jansen M, Santer R, Johannsen J, Bacchelli C, Alders M, Li R, Davies R, Dupuis L, Cale C, Wanders R, Pals S, Ocaka L, James C, Müller I, Lehmberg K, Strom T, Engels H, Williams H, Beales P, Roepman R, Dias P, Brunner H, Cobben J, Hall C, Hartley T, Le Quesne Stabej P, Mendoza-Londono R, Davies E, de Sousa S, Lessel D, Arts H, Kuijpers T
AM J HUM GENET. 2017;100(2):281-296.

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement
Zoghbi A, Zur Stadt U, Winkler B, Müller I, Escherich G
PEDIATR BLOOD CANCER. 2017 [Epub ahead of print].

2016

Feasibility of CD3/CD19 depletion of a bone marrow graft
Bonig H, Müller I
CYTOTHERAPY. 2016;18(10):1345-7.

Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
Decarolis B, Simon T, Krug B, Leuschner I, Vokuhl C, Kaatsch P, von Schweinitz D, Klingebiel T, Müller I, Schweigerer L, Berthold F, Hero B
BMC CANCER. 2016;16:542.

Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients
Döring M, Cabanillas Stanchi K, Feucht J, Queudeville M, Teltschik H, Lang P, Feuchtinger T, Handgretinger R, Müller I
ANN HEMATOL. 2016;95(2):311-23.

Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients
Groeschel S, Kühl J, Bley A, Kehrer C, Weschke B, Döring M, Böhringer J, Schrum J, Santer R, Kohlschütter A, Krägeloh-Mann I, Müller I
JAMA NEUROL. 2016;73(9):1133-40.

The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis
Hartz B, Marsh R, Rao K, Henter J, Jordan M, Filipovich L, Bader P, Beier R, Burkhardt B, Meisel R, Schulz A, Winkler B, Albert M, Greil J, Karasu G, Woessmann W, Corbaciologlu S, Gruhn B, Holter W, Kühl J, Lang P, Seidel M, Veys P, Löfstedt A, Ammann S, Ehl S, Janka G, Müller I, Lehmberg K
BLOOD. 2016;127(25):3281-90.

Treosulfan based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicentre experience
Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano J, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo M, Veys P, Sykora K, Gennery A, Slatter M
BLOOD. 2016;128(3):440-8.

Fracture Healing Is Delayed in Immunodeficient NOD/scid‑IL2Rγcnull Mice
Rapp A, Bindl R, Recknagel S, Erbacher A, Müller I, Schrezenmeier H, Ehrnthaller C, Gebhard F, Ignatius A
PLOS ONE. 2016;11(2):e0147465.

Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation
Schmidt M, Breyer S, Löbel U, Yarar S, Stücker R, Ullrich K, Müller I, Muschol N
ORPHANET J RARE DIS. 2016;11(1):93.

Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients
Teltschik H, Heinzelmann F, Gruhn B, Feuchtinger T, Schlegel P, Schumm M, Kremens B, Müller I, Ebinger M, Schwarze C, Ottinger H, Zips D, Handgretinger R, Lang P
BRIT J HAEMATOL. 2016;175(1):115-22.

2015

Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert M, Willasch A, Klingebiel T, Peters C
J CLIN ONCOL. 2015;33(11):1275 - 84.

Consensus of German transplant centers on hematopoietic stem cell transplantation in Fanconi anemia
Chao M, Ebell W, Bader P, Beier R, Burkhardt B, Feuchtinger T, Handgretinger R, Hanenberg H, Koehl U, Kratz C, Kremens B, Lang P, Meisel R, Müller I, Roessig C, Sauer M, Schlegel P, Schulz A, Strahm B, Thol F, Sykora K
KLIN PADIATR. 2015;227(3):157-65.

Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation
Döring M, Cabanillas Stanchi K, Mezger M, Erbacher A, Feucht J, Pfeiffer M, Lang P, Handgretinger R, Müller I
BMC CANCER. 2015;15:Art. 607.

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
Döring M, Eikemeier M, Cabanillas Stanchi K, Hartmann U, Ebinger M, Schwarze C, Schulz A, Handgretinger R, Müller I
EUR J CLIN MICROBIOL. 2015;34(6):1189-1200.

Multipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?
Johann P, Müller I
Stem Cells Int. 2015;2015:914632.

Risk of Rotavirus Vaccination for Children with SCID
Klinkenberg D, Blohm M, Hoehne M, Mas Marques A, Malecki M, Schildgen V, Schneppenheim R, Müller I, Schildgen O, Kobbe R
PEDIATR INFECT DIS J. 2015;34(1):114-5.

Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients
Kruchen A, Stahl T, Gieseke F, Binder T, Özcan Z, Meisel R, Kreyenberg H, Bader P, Gruhn B, Greil J, Pfeiffer M, Döring M, Handgretinger R, Fehse B, Müller I
BONE MARROW TRANSPL. 2015;50(10):1367-1370.

Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents
Lehmberg K, Sprekels B, Nichols K, Woessmann W, Müller I, Suttorp M, Bernig T, Beutel K, Bode S, Kentouche K, Kolb R, Längler A, Minkov M, Schilling F, Schmid I, Vieth S, Ehl S, Zur Stadt U, Janka G
BRIT J HAEMATOL. 2015;170(4):539-49.

Klinische Praxis - Spenderfindung und Stammzelltransplantation
Müller I
2015. Rettende Geschwister. Schües C, Rehmann-Sutter C (Hrsg.). 2015. Aufl. Münster: Mentis, 25 - 32.

Systemic mesenchymal stem cell administration enhances bone formation in fracture repair but not load-induced bone formation
Rapp A, Bindl R, Heilmann A, Erbacher A, Müller I, Brenner R, Ignatius A
EUR CELLS MATER. 2015;29:22-34.

Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications
Wuchter P, Bieback K, Schrezenmeier H, Bornhäuser M, Müller L, Bönig H, Wagner W, Meisel R, Pavel P, Tonn T, Lang P, Müller I, Renner M, Malcherek G, Saffrich R, Buss E, Horn P, Rojewski M, Schmitt A, Ho A, Sanzenbacher R, Schmitt M
CYTOTHERAPY. 2015;17(2):128-139.

2014

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
Döring M, Blume O, Haufe S, Hartmann U, Kimmig A, Schwarze C, Lang P, Handgretinger R, Müller I
EUR J CLIN MICROBIOL. 2014;33(4):629-38.

Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia
Lang P, Teltschik H, Feuchtinger T, Müller I, Pfeiffer M, Schumm M, Ebinger M, Schwarze C, Gruhn B, Schrauder A, Albert M, Greil J, Urban C, Handgretinger R
BRIT J HAEMATOL. 2014;165(5):688-98.

Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis
Lehmberg K, Albert M, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I
HAEMATOLOGICA. 2014;99(1):180-4.

Signal-peptide-peptidase-like 2a is required for CD74 intramembrane proteolysis in human B cells
Schneppenheim J, Hüttl S, Kruchen A, Fluhrer R, Müller I, Saftig P, Schneppenheim R, Martin C, Schröder B
BIOCHEM BIOPH RES CO. 2014;451(1):48-53.

2013

Allo-SCT using BU, CY and melphalan for children with AML in second CR
Beier R, Albert M, Bader P, Borkhardt A, Creutzig U, Eyrich M, Ehlert K, Gruhn B, Greil J, Handgretinger R, Holter W, Klingebiel T, Kremens B, Lang P, Mauz-Körholz C, Meisel R, Müller I, Peters C, Reinhardt D, Sedlacek P, Schulz A, Schuster F, Schrauder A, Strahm B, Sykora K, Wössmann W, Zimmermann M, Sauer M
BONE MARROW TRANSPL. 2013;48(5):651-6.

Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience
Beier R, Schulz A, Hönig M, Eyrich M, Schlegel P, Holter W, Stachel K, Ehlert K, Greil J, Nürnberger W, Wössmann W, Bader P, Urban C, Müller I, Suttorp M, Sauer M, Gruhn B, Meisel R, Zimmermann M, Sykora K
BONE MARROW TRANSPL. 2013;48(4):491-501.

Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation
Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I
EUR J IMMUNOL. 2013;43(10):2741-9.

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion
Höchst B, Schildberg F, Sauerborn P, Gäbel Y, Gevensleben H, Goltz D, Heukamp L, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle P, Diehl L
J HEPATOL. 2013;59(3):528-35.

One goal, different strategies--molecular and cellular approaches for the treatment of inherited skin fragility disorders
Hünefeld C, Mezger M, Kern J, Nyström A, Bruckner-Tuderman L, Müller I, Handgretinger R, Röcken M
EXP DERMATOL. 2013;22(3):162-7.

Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort
Krägeloh-Mann I, Groeschel S, Kehrer C, Opherk K, Nägele T, Handgretinger R, Müller I
BONE MARROW TRANSPL. 2013;48(3):369-75.

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.
Marsh R, Rao K, Satwani P, Lehmberg K, Müller I, Li D, Kim M, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis D, Dimmock D, Casper J, Douglas D, Amrolia P, Veys P, Kumar A, Jordan M, Bleesing J, Filipovich A
BLOOD. 2013;121(6):877-883.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

2012

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens J, Hewitt A, Schrum J, Schulz A, Müller I, Stein J, Wynn R, Greil J, Sykora K, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel P, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin K, Peters C, Dini G
LANCET. 2012;379(9823):1301-1309.

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Döring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, Müller I
BMC INFECT DIS. 2012;12:151.

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
Döring M, Müller C, Johann P, Erbacher A, Kimmig A, Schwarze C, Lang P, Handgretinger R, Müller I
BMC INFECT DIS. 2012;12:263.

Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia.
Döring M, Zierl A, Mezger M, Lang P, Handgretinger R, Müller I
Case Rep Transplant. 2012;2012:672923.

Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts.
Gieseke F, Mang P, Viebahn S, Sonntag I, Kruchen A, Erbacher A, Pfeiffer M, Handgretinger R, Müller I
EUR J IMMUNOL. 2012;42(8):2176-2186.

Basic biology and clinical application of multipotent mesenchymal stromal cells
Kuçi S, Henschler R, Müller I, Biagi E, Meisel R
Stem Cells Int. 2012;2012:185943.

Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside.
Kuçi S, Henschler R, Müller I, Biagi E, Meisel R
Stem Cells Int. 2012;2012:185943.

IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT.
Pfeiffer M, Schumm M, Müller I, Handgretinger R, Lang P
LEUKEMIA. 2012;26(11):2435-2439.

2011

Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology.
Gómez-Barrena E, Rosset P, Müller I, Giordano R, Bunu C, Layrolle P, Konttinen Y, Luyten F
J CELL MOL MED. 2011;15(6):1266-1286.

Increased cyclosporine concentrations in the absence of cyclosporine administration.
Peter A, Shipkova M, Wieland E, Schleicher E, Müller I
CLIN CHEM. 2011;57(5):670-673.

Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases.
Wernicke C, Grunewald T, Juenger H, Kuci S, Kuci Z, Koehl U, Müller I, Doering M, Peters C, Lawitschka A, Kolb H, Bader P, Burdach S, von Luettichau I
Int Arch Med. 2011;4(1):27.

2010

Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells
Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I
BLOOD. 2010;116(19):3770-9.

Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells
Holzwarth C, Vaegler M, Gieseke F, Pfister S, Handgretinger R, Kerst G, Müller I
BMC CELL BIOL. 2010;11:11.

Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity
Johann P, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, Handgretinger R, Müller I
BMC CANCER. 2010;10:501.

Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children
Pfeiffer M, Feuchtinger T, Teltschik H, Schumm M, Müller I, Handgretinger R, Lang P
HAEMATOLOGICA. 2010;95(8):1381-8.

Chronic inflammatory bowel disease as key manifestation of atypical ARTEMIS deficiency
Rohr J, Pannicke U, Döring M, Schmitt-Graeff A, Wiech E, Busch A, Speckmann C, Müller I, Lang P, Handgretinger R, Fisch P, Schwarz K, Ehl S
J CLIN IMMUNOL. 2010;30(2):314-20.

2009

Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany
Schäfer R, Dominici M, Müller I, Horwitz E, Asahara T, Bulte J, Bieback K, Le Blanc K, Bühring H, Capogrossi M, Dazzi F, Gorodetsky R, Henschler R, Handgretinger R, Kajstura J, Kluger P, Lange C, Luettichau I, Mertsching H, Schrezenmeier H, Sievert K, Strunk D, Verfaillie C, Northoff H
CYTOTHERAPY. 2009;11(2):245-55.

2007

Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation
Handgretinger R, Chen X, Pfeiffer M, Müller I, Feuchtinger T, Hale G, Lang P
ANN NY ACAD SCI. 2007;1106:279-89.

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients
Lang P, Müller I, Greil J, Bader P, Schumm M, Pfeiffer M, Hoelle W, Klingebiel T, Heinzelmann F, Belka C, Schlegel P, Kremens B, Woessmann W, Handgretinger R
BLOOD CELL MOL DIS. 2007;40(1):33-9.

2006

Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM
Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz M, Horwitz E, Conte P, Handgretinger R, Dominici M
CYTOTHERAPY. 2006;8(5):437-44.

Letzte Aktualisierung aus dem FIS: 17.07.2017 - 00:04 Uhr